ArticleJapanese journal of ophthalmology2025
Bacteriologic profile and antimicrobial resistance in infants aged 1 year or younger with congenital nasolacrimal duct obstruction.
Article in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the study was to evaluate conjunctival flora and antibiotic susceptibility in infants aged 1 year or younger with congenital nasolacrimal duct obstruction (CNLDO), creating an overall profile of antimicrobial susceptibility. STUDY
designRetrospective.
methodsThe analysis was conducted at the Kazakh Eye Research Institute over a period of 6 years, from January 2017 to December 2022. Cultures were grown on various agars for bacterial and fungal analyses, with sensitivity testing via Vitek 2 Compact.
resultsWe examined 1210 conjunctival cultures from infants with CNLDO, yielding 1212 isolates. Most were gram-positive bacteria (77.15%), with fewer gram-negative bacteria (22.28%) and fungi (0.57%). Among the gram-positive bacteria, Staphylococcus species (61.06%) were predominant, including S epidermidis (17.49%), S aureus (10.73%), and S saprophyticus (9.32%). Enterococcus species (6.52%) and Streptococcus species (6.02%) followed. Among the gram-negative bacteria, Escherichia coli (5.78%) was most prevalent, followed by Pseudomonas species. (4.54%), Enterobacter cloacae (3.71%), and Klebsiella species (3.63%). The majority of the fungi were Candida albicans, accounting for 4 isolates (0.33%). Most of the bacteria showed high sensitivity to moxifloxacin (92.52%), levofloxacin (88.99%), gentamicin (86.74%), vancomycin (86.52%), cefotaxime (85.27%), and ofloxacin (85.62%). High resistance was noted for erythromycin (32.84%), clindamycin (28.13%), and tetracycline (21.65%).
conclusionIn this study, we identified Staphylococcus, Enterococcus, and Streptococcus species and E coli as key CNLDO bacteria and highly responsive to antibiotics like levofloxacin and moxifloxacin. These findings guide effective antibiotic choices for CNLDO treatment, aiding in the prevention of antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.